For more information about any of these resources, please click the Request More information button below and provide the listed Resource ID#.
Model (cell/organoid/animal) for COVID-19
Resource ID#: 188
The Wake Forest Institute for Regenerative Medicine has developed a “body on a chip” platform that has demonstrated exceptional performance in modeling normal and pathological human physiology. The platform includes a perfused microfluidic system connecting a series of tissue chambers, each housing a different microengineered organ/tissue equivalent (OTE). Solid organs are represented as 3D spherical structures, while the lung construct is arranged in a pseudostratified architecture and includes an epithelial air interface with underlying interstitium and endothelial fluid interface. Production of mucus and surfactant provides a physiologically relevant mechanical barrier, a critical factor for modeling viral infectivity in a realistic manner. Additionally, the lung OTE epithelial cells become ciliated to a degree equivalent to that of native lung. This is important, as it dramatically increases the surface area to which virus may attach. These phenotypic characteristics increase the fidelity of the OTE for modeling viral infection kinetics. The presence of immune cells and fibroblasts in the interstitium also allows for modeling of inflammation and subsequent fibrosis, respectively. ACE-2 receptor, the port of cellular entry for SARS-CoV-2, has been demonstrated on the epithelial cells of the lung OTE at levels similar to those seen in native lung. Preliminary studies show that SARS-CoV-2 is able to infect these lung OTE constructs and that the infection propagates and spreads within the system. One of the major benefits of this model is the ability to include downstream OTEs in the microfluidic circuit. For SARS-CoV-2 infections this is critical, as many tissue types including liver, cardiac, and vasculature have been implicated in the overall pathology of COVID-19. Because these constructs are engineered from populations of donor derived human cells, the role of specific cell types in the disease process may be modeled. For instance, epithelial cells from an elderly donor may be matched with macrophages from a younger donor, and vice versa. This opens the potential for conducting studies for uncovering the mechanism that drive many of the unique epidemiological characteristics that have been observed in COVID-19.
Resource ID#: 192
Allevi is using its state-of-the-art 3D bioprinting platform to fabricate SARS-CoV-2-infected, human airway and lung organoid models. These models are being used to study COVID-19 disease progression and for rapid drug screening.
Allevi's commercially available 3D bioprinters enable automated biofabrication of a variety of tissue types.
Resource ID#: 193
Human Organ-on-a-chip in vitro culture devices can be used to model human lung airway epithelium microenvironment to study SAR-Cov-2 (COVID-19) diseases pathogenesis such as virus entry, replication, strain-dependent virulence, host cytokine production, and recruitment of circulating immune cells in response to infection, as well as to study the effect of existing and novel therapeutics on the infected epithelium. The human Airway Chips have provided a more stringent and physiologically relevant platform to assess inhibitory activities of several clinically approved drugs under dynamic flow condition to expedite drug repurposing for considerations in future clinical testing reported in the two following publications.
The Organ-on-Chip technology was initially developed at the Wyss Institute, Harvard University, and is now commercially available through Emulatebio company.
Cell Therapy for COVID-19
Resource ID#: 191
Existing Approved Clinical Trial about to begin recruitment for management/treatment of post-COVID-19 lung damage.
Citation: Alexander, Robert W., (2020) Overview of COVID-19 Lung Damage Clinical Trial Using Cellular Stromal Vascular Fraction (cSVF) and Functional Respiratory Imaging (FRI): Analysis of Pulmonary Injury & Post-Viral (SARS-CoV)-2 Adult Respiratory Distress Syndrome (ARDS). Stem Cell Res. 1(1): 1-19.
Technology for Fighting COVID-19
Resource ID#: 187
Our Xvivo System is a next generation isolator that can provide physiologically relevant gas levels and temperatures for cell incubation as well as cell handling. Available for cGMP-compliant aseptic cell production, the modular Xvivo System is rapidly deployable and already in use for generating human cells for COVID-19 clinical trials.
We also design and build equipment for researchers looking to provide physiologically relevant conditions to cells in their labs for better scientific reproducibility and faster translatability. The world is waiting for new answers to this global pandemic. We can help you find them. Check out our laboratory equipment here: https://www.biospherix.com/covid-19
Resource ID#: 191
Orbital Transports, Inc. has developed a solution for performing cellular and molecular research on CubeSats, and returning the research materials to the scientists. This enables new opportunities for space-based research that can be conducted without human intervention, and thus free scientists from crew time and other limitations inherent to the International Space Station. Also, polar orbits are particularly useful for research requiring exposure to space radiation, and these are not accessible via the International Space Station.
Additional information: https://catalog.orbitaltransports.com/bio-payload-experiment/